知镜 Cognispect · 医学文献与研究工作台

A review of genetic and epigenetic biomarkers involved in the occurrence of atypical hemolytic uremic syndrome and its therapeutic strategies.

Tohidi M, Mohammadi M.
Molecular biology reports · 2026-05-14 · PMID 42133203

文献摘要

Atypical hemolytic uremic syndrome (aHUS) is a rare, chronic, and life-threatening thrombotic microangiopathy (TMA). The disease is most frequently linked to genetic or acquired dysregulation of the alternative complement pathway and affects both children and adults. The paucity of a gold standard for diagnostic testing and the variety of clinical manifestations are the primary reasons for the challenge in accurately diagnosing aHUS, which can have an impact on patient care. This is due to the fact that the more prevalent autoinflammatory diseases are multifactorial in nature, with both genetic and non-genetic factors playing critical roles. Until the last decade, treatment options were limited to plasma therapy and, in selected cases, liver transplantation, neither of which directly addressed the underlying pathophysiology and both of which carried substantial risks. Since its introduction in 2011, the anti-C5 monoclonal antibody eculizumab has significantly improved outcomes and transformed disease management. Trials on novel complement inhibitors, regenerative medicine, targeted therapy, and stem cell therapy may also improve future treatment options. The primary objectives of this investigation are to identify the genetic and epigenetic causes of aHUS, as well as the limitations and debates surrounding its management. Due to the prevalence and significance of this type of illness, researchers have investigated effective therapeutic methods and more recent approaches.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。